ABSI Stock Overview
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Absci Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.35 |
| 52 Week High | US$9.68 |
| 52 Week Low | US$1.94 |
| Beta | 0 |
| 1 Month Change | 40.76% |
| 3 Month Change | 15.12% |
| 1 Year Change | -53.47% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -84.48% |
Recent News & Updates
Recent updates
Absci GAAP EPS of -$0.32 misses by $0.01, revenue of $1M misses by $0.68M
Aug 11Absci teams up to help develop antibody drugs for cancer
Jul 07Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out
Jan 10IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)
Jul 22Shareholder Returns
| ABSI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.8% | -0.8% | 1.7% |
| 1Y | -53.5% | 4.4% | -9.6% |
Return vs Industry: ABSI underperformed the US Biotechs industry which returned 4.5% over the past year.
Return vs Market: ABSI underperformed the US Market which returned -8.5% over the past year.
Price Volatility
| ABSI volatility | |
|---|---|
| ABSI Average Weekly Movement | 15.9% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ABSI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: ABSI's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 212 | Sean McClain | https://www.absci.com |
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Absci Corporation Fundamentals Summary
| ABSI fundamental statistics | |
|---|---|
| Market Cap | US$309.52m |
| Earnings (TTM) | -US$110.60m |
| Revenue (TTM) | US$5.64m |
54.9x
P/S Ratio-2.8x
P/E RatioIs ABSI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABSI income statement (TTM) | |
|---|---|
| Revenue | US$5.64m |
| Cost of Revenue | US$63.36m |
| Gross Profit | -US$57.72m |
| Other Expenses | US$52.88m |
| Earnings | -US$110.60m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | -1,022.99% |
| Net Profit Margin | -1,960.28% |
| Debt/Equity Ratio | 3.0% |
How did ABSI perform over the long term?
See historical performance and comparison